|
1
|
Carey WD: The prevalence and natural
history of hepatitis B in the 21st century. Cleve Clin J Med.
76(Suppl 3): S2–S5. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lai M and Liaw YF: Chronic hepatitis B:
Past, present, and future. Clin Liver Dis. 14:531–546. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lavanchy D: Hepatitis B virus
epidemiology, disease burden, treatment, and current and emerging
prevention and control measures. J Viral Hepat. 11:97–107. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Liu J, Zhang S, Wang Q, Shen H, Zhang M,
Zhang Y, Yan D and Liu M: Seroepidemiology of hepatitis B virus
infection in 2 million men aged 21-49 years in rural China: A
population-based, cross-sectional study. Lancet Infect Dis.
16:80–86. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lutgehetmann M, Volz T, Köpke A, Broja T,
Tigges E, Lohse AW, Fuchs E, Murray JM, Petersen J and Dandri M: In
vivo proliferation of hepadnavirus-infected hepatocytes induces
loss of covalently closed circular DNA in mice. Hepatology.
52:16–24. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Spangenberg HC, Thimme R and Blum HE:
Tracking cccDNA in chronic HBV infection. Hepatology. 39:1736–1738.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Levrero M, Testoni B and Zoulim F: HBV
cure: Why, how, when? Curr Opin Virol. 18:135–143. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Daoud FS: Branchial cyst: An often
forgotten diagnosis. Asian J Surg. 28:174–178. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kann M, Bischof A and Gerlich WH: In vitro
model for the nuclear transport of the hepadnavirus genome. J
Virol. 71:1310–1316. 1997.PubMed/NCBI
|
|
10
|
Li GQ, Gu HX, Li D and Xu WZ: Inhibition
of Hepatitis B virus cccDNA replication by siRNA. Biochem Biophys
Res Commun. 355:404–408. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Watashi K, Urban S, Li W and Wakita T:
NTCP and Beyond: Opening the door to unveil hepatitis B virus
entry. Int J Mol Sci. 15:2892–2905. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Abou-Jaoudé G and Sureau C: Entry of
hepatitis delta virus requires the conserved cysteine residues of
the hepatitis B virus envelope protein antigenic loop and is
blocked by inhibitors of thiol-disulfide exchange. J Virol.
81:13057–13066. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yan H, Zhong G, Xu G, He W, Jing Z, Gao Z,
Huang Y, Qi Y, Peng B, Wang H, et al: Sodium taurocholate
cotransporting polypeptide is a functional receptor for human
hepatitis B and D virus. Elife. 1:e000492012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Claro da Silva T, Polli JE and Swaan PW:
The solute carrier family 10 (SLC10): Beyond bile acid transport.
Mol Aspects Med. 34:252–269. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kullak-Ublick GA, Beuers U and Paumgartner
G: Molecular and functional characterization of bile acid transport
in human hepatoblastoma HepG2 cells. Hepatology. 23:1053–1060.
1996. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kotani N, Maeda K, Debori Y, Camus S, Li
R, Chesne C and Sugiyama Y: Expression and transport function of
drug uptake transporters in differentiated HepaRG cells. Mol Pharm.
9:3434–3441. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wen WH, Liu JY, Qin WJ, Zhao J, Wang T,
Jia LT, Meng YL, Gao H, Xue CF, Jin BQ, et al: Targeted inhibition
of HBV gene expression by single-chain antibody mediated small
interfering RNA delivery. Hepatology. 46:84–94. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wen WH, Qin WJ, Gao H, Zhao J, Jia LT,
Liao QH, Meng YL, Jin BQ, Yao LB, Chen SY, et al: An hepatitis B
virus surface antigen specific single chain of variable fragment
derived from a natural immune antigen binding fragment phage
display library is specifically internalized by HepG2.2.15 cells. J
Viral Hepat. 14:512–519. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Manasseh D: Protamine binding location on
DNA. 1995.
|
|
20
|
Ko C, Park WJ, Park S, Kim S, Windisch MP
and Ryu WS: The FDA-approved drug irbesartan inhibits HBV-infection
in HepG2 cells stably expressing sodium taurocholate
co-transporting polypeptide. Antivir Ther. 20:835–842. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Mcfarland AP, Horner SM, Jarret A, Joslyn
RC, Bindewald E, Shapiro BA, Delker DA, Hagedorn CH, Carrington M,
Gale M Jr, et al: The favorable IFNL3 genotype escapes mRNA decay
mediated by AU-rich elements and hepatitis C virus-induced
microRNAs. Nat Immunol. 15:72–79. 2014. View Article : Google Scholar
|
|
22
|
Urban TJ, Thompson AJ, Bradrick SS, Fellay
J, Schuppan D, Cronin KD, Hong L, McKenzie A, Patel K, Shianna KV,
et al: IL28B genotype is associated with differential expression of
intrahepatic interferon-stimulated genes in patients with chronic
hepatitis C. Hepatology. 52:1888–1896. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Gane EJ: Future anti-HBV strategies. Liver
Int. 37(Suppl 1): S40–S44. 2017. View Article : Google Scholar
|
|
24
|
Veloso Alves Pereira I, Buchmann B,
Sandmann L, Sprinzl K, Schlaphoff V, Döhner K, Vondran F, Sarrazin
C, Manns MP, Pinto Marques Souza de Oliveira C, et al: Primary
biliary acids inhibit hepatitis D virus (HDV) entry into human
hepatoma cells expressing the sodium-taurocholate cotransporting
polypeptide (NTCP). PLoS One. 10:e01171522015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Shen ZW, Luo MY, Hu HH, Zhou H, Jiang HD,
Yu LS and Zeng S: Screening and verifying potential NTCP inhibitors
from herbal medicinal ingredients using the LLC-PK1 cell model
stably expressing human NTCP. Chin J Nat Med. 14:549–560.
2016.PubMed/NCBI
|
|
26
|
Donkers J, Zehnder B, van Westen GJP,
Kwakkenbos MJ, IJzerman AP, Oude Elferink RPJ, Beuers U, Urban S
and van de Graaf SFJ: Reduced hepatitis B and D viral entry using
clinically applied drugs as novel inhibitors of the bile acid
transporter NTCP. Sci Rep. 7:153072017. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Chen YM, Yin B, Guo XC, Wang W, Zheng Q,
Wang F, Sun D, Li D, Ren G and Yin J: Selection of
affinity-improved neutralizing human scFv against HBV PreS1 from
CDR3 VH/VL mutant library. Biologicals. 44:271–275. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wang H, Yang Y, Wang W, Guan B, Xun M,
Zhang H, Wang ZL and Zhao Y: Construction and verification of
anti-MM scFv-tP fusion protein expression vector. Nan Fang Yi Ke Da
Xue Xue Bao. 1149–1155. 2017.In Chinese.
|
|
29
|
Marimani M, Hean J, Bloom K, Ely A and
Arbuthnot P: Recent advances in developing nucleic acid-based HBV
therapy. Future Microbiol. 8:1489–1504. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Xu Z, Chavez D, Guerra B, Littlejohn M,
Peterson R, Locarnini S, Gish R, Anzalone C, Kanner S, Goetzmann J,
et al: Treatment of chronically HBV-infected chimpanzees with RNA
interference therapeutic ARC-520 LED to potent reduction of viral
MRNA, DNA and proteins without observed drug resistance. J Hepatol.
64:S398. 2016. View Article : Google Scholar
|
|
31
|
Yuen MF, Chan HLY, Liu K, Given BD,
Schluep T, Hamilton J, Lai CL, Locarnini SA, Lau JYN, Ferrari C and
Gish RG: Differential reductions in viral antigens expressed from
CCCDNAVS integrated DNA in treatment Naïve HBEAG positive and
negative patients with chronic HBV after RNA interference therapy
with ARC-520. J Hepatol. 64:S390–S391. 2016. View Article : Google Scholar
|
